Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRDN-003 in Thyroid Eye Disease
NCT07155668Phase 3Completed
- Sponsor
- Viridian Therapeutics
- Start
- Jul 2025
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of elegrobart in thyroid eye disease (TED), sponsored by Viridian Therapeutics. Started Jul 2025; status: completed.
02
Drugs
elegrobart
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT07155668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07155668.